Viatris (VTRS) is an S&P 500 company in Pharmaceuticals. It grades strongest on value and weakest on growth and profitability.
Where VTRS ranks among the 1,500 U.S. stocks the model scores each trading day, its expected return, the evidence for and against it, and whether the model portfolio holds it. The grades below describe the company's data; they are not the model's view.
See plansTotal returns with dividends reinvested.
Each grade compares VTRS with the rest of its sector (A+ best, F worst); the numbers behind it are shown with the typical figure for its peers.
| Market value | $20.2B |
| Enterprise value | $32.7B |
| Price / sales | 1.4x |
| Price / book | 1.4x |
| EV / revenue | 2.2x |
| EV / EBITDA | 12.0x |
| Revenue, last 12 months | $14.7B |
| EPS, last 12 months (GAAP) | $-0.36 |
| Gross margin | 34.8% |
| Operating margin | -0.6% |
| Return on invested capital | -0.3% |
| Cash | $886.5M |
| Total debt | $13.3B |
| Debt / equity | 0.94x |
| Free cash flow, last 12 months | $2.0B |
| Current ratio | 1.58x |
Company figures from its latest SEC filings; market value and returns from end-of-day prices.
From the company's 10-Q and 10-K filings with the SEC.
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |
| EPS (GAAP) | $-1.05 | $1.71 | $0.05 | $-0.53 | $-2.96 |
| Free cash flow | $2.6B | $2.5B | $2.4B | $2.0B | $1.9B |
| Reported | EPS (GAAP) | EPS y/y | Revenue y/y | Stock vs S&P 500, 2 days |
|---|---|---|---|---|
| 2026-08-06 | $-0.10 | n/a | +5% | -7.4% |
| 2026-05-07 | $0.15 | n/a | +8% | +7.1% |
| 2026-02-26 | $-0.30 | n/a | +5% | -6.1% |
| 2025-11-06 | $-0.11 | -238% | +0% | -4.9% |
| 2025-08-07 | $0.00 | n/a | -6% | +10.2% |
| 2025-05-08 | $-2.55 | -2933% | -11% | +1.4% |
From the company's SEC registration record.
| Company | Market value | P/E | Revenue growth | Operating margin | 12-month change | |
|---|---|---|---|---|---|---|
| VTRS Viatris | $20.2B | n/a | +4% | -0.6% | +79% | |
| ZTS Zoetis | $29.5B | 11.8x | +1% | n/a | -50% | compare |
| BMY Bristol-Myers Squibb | $120.1B | 13.0x | +3% | n/a | +35% | compare |
| PFE Pfizer | $156.2B | 36.1x | -0% | n/a | +7% | compare |
| MRK Merck | $344.3B | 110.7x | +5% | n/a | +61% | |
| JNJ Johnson & Johnson | $609.5B | 29.3x | +8% | n/a | +37% | |
| LLY Eli Lilly | $1.1T | 38.4x | +50% | n/a | +37% |
Torvanta does not tell individuals what to buy. Its grades for VTRS are shown above. Subscribers see the model's rank, expected return and whether the model portfolio holds it. This is research, not a recommendation.
Based on its filing history, Torvanta expects Viatris to report around 2026-11-05.
Yes. Its dividend yield is about 2.7%.
Over the past year VTRS returned +78.9%, against +17.0% for the S&P 500, dividends reinvested.
Subscribers get the model's rank and expected return for every covered company, the reasoning behind each, and the Torvanta model portfolio's trades each trading day, sized and explained, at three risk levels.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer